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Abstract
Effectors from the immune system can modulate the course and possibly the early 
development of gliomas. We, therefore, hypothesized that autoimmune diseases as-
sociated with increased immune-surveillance may also modulate the risk of human 
glioma. To test this hypothesis, we used data from the well-validated Clinical 
Practice Research Datalink (CPRD) GOLD from the UK to analyze the associa-
tion of immune-related disorders or use of immunosuppressive drugs and the risk of 
glioma. We identified 3112 incident glioma cases diagnosed between 1995 and 2017. 
We randomly selected up to 10 controls, matching them to glioma cases on age, sex, 
index date, general practice, and number of years of active history in the database 
prior to the index date. We performed conditional logistic regression analyses to es-
timate Odds Ratios (ORs) of glioma among those exposed to allergies, autoimmune 
diseases, and immunosuppressive drugs. Overall, we found no materially altered as-
sociation between a history of any autoimmune disease (OR 0.98, 95% CI 0.86-1.11), 
allergy (OR 0.97, 95% CI 0.89-1.05), or use of immunosuppressive drugs and the risk 
of glioma. However, subgroup analyses among younger patients found a statistically 
significant increased risk of glioma in patients with a history of inflammatory bowel 
disease (IBD) (OR 2.59, 95% CI 1.31-5.12). There was also an inverse association 
between asthma and risk of glioma in patients with longer survival (OR 0.73, 95% 
CI 0.58-0.91) and between long-term duration diabetes and risk of glioma (OR 0.71, 
95% CI 0.53-0.96).
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1 |  INTRODUCTION
Gliomas are primary brain tumours and glioblastoma is the 
most common type of glioma.1 Despite standard therapy 
with resection, combined radio-chemotherapy, and adjuvant 
chemotherapy with tumor-treating fields, glioblastomas still 
have a median survival of only 20.9 months.2 Ionizing radia-
tion is the only known environmental factor associated with 
increased risk of brain tumors.3
Current understanding indicates various interaction mech-
anisms between the immune system and the central nervous 
system (CNS). Using specific lymphatic vessels, antigens and 
immune cells from the cerebral fluid drain into the deep cer-
vical lymph nodes, thus interacting with the immune system.4 
Furthermore, in diseases such as autoimmune encephalitis, 
neurodegenerative diseases, and brain tumors, immune cells 
from the blood migrate to the CNS.5-7 Antigen-presenting 
cells are predominantly located in perivascular spaces, allow-
ing T-cell reactivation8 which subsequently triggers immuno-
logical events.
Despite good response rates to immunotherapy in a 
couple of solid tumor entities such as lung cancer or mel-
anoma,9,10 introduction of these therapeutics in neuro-on-
cology has not yet improved survival in glioblastoma.11 
Therefore, further understanding of tumor biology and 
mechanisms of immune modulation in glioblastoma is 
crucial for the development of new immunotherapeutic 
approaches.
Autoimmune diseases (AD) are typically character-
ized by the presence of autoreactive immune cells and 
the production of autoantibodies.12 However, T-cells 
exert distinct effects in glioma and autoimmune disease. 
In contrast to multiple sclerosis, regulatory T-cell (Treg) 
function is preserved in glioma and thus, Tregs are able 
to maintain peripheral tolerance in patients with glioma.13 
This raises the question of whether the activated immune 
system in autoimmune disorders may be able to induce 
an immune-response against transformed glioma cells that 
show “foreign” epitopes on their surface,14 which could 
translate into a preventive effect against glioma develop-
ment and a decreased incidence of gliomas in patients with 
history of AD.
A number of studies have investigated the risk of brain tu-
mors in relation to immune-related conditions. Several stud-
ies observed a reduced risk of glioma in patients with history 
of allergies15-21 and autoimmune diseases,15,22 while others 
found no significant associations.16,23-25
In order to provide more data on these questions, we 
conducted a comprehensive examination of immune-re-
lated disorders and intake of immunosuppressive drugs 
with regard to glioma risk, using primary-care data from 
the UK
2 |  MATERIALS AND METHODS
2.1 | Data source
The Clinical Practice Research Datalink (CPRD) GOLD is 
a large longitudinal database, which encompasses patient 
information on over 11 million patients from around 670 
general practices representative of the UK population with 
respect to sex, age, and ethnicity. The CPRD GOLD in-
cludes medical records on over 11 million patients with ac-
ceptable quality for research based on data quality checks.26 
The validity of information in the CPRD GOLD has been 
thoroughly documented and found to be of high quality for 
research purposes.26,27
We received approval from the Independent Scientific 
Advisory Committee for Medicines and Healthcare products 
Regulatory Agency database research (ISAC, protocol num-
ber 16_158R). The study protocol was made available for 
reviewers/editors.
Data for this study were derived from CPRD primary 
care data obtained under license from the UK Medicines and 
Healthcare products Regulatory Agency. The data are pro-
vided by patients and collected by the NHS as part of their 
care and support. The interpretation and conclusions con-
tained in this study are those of the authors alone.
2.2 | Study population
2.2.1 | Cases
As described previously28-30 we used medical READ codes 
to identify cases. We defined cases as patients under 90 years 
of age, with newly diagnosed, incident glioma between 1995 
and 2017. We defined the date of the first diagnosis of glioma 
minus 1 year as “index date”. We implemented this 1 year 
shift backwards in time in order to account for potential treat-
ment of early symptoms during glioma development and be-
fore diagnosis.
We applied the same other inclusion and exclusion crite-
ria as in our previous glioma studies, which are described in 
detail there.28-30
2.2.2 | Controls
The selection of controls is analogous to our previous gli-
oma studies. We randomly selected up to 10 controls with-
out a history of glioma in the CPRD and matched them to 
glioma cases on age, sex, index date, general practice, and 
number of years of active history in the CPRD prior to the 
index date.
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We applied the same exclusion criteria to controls as to 
cases and additionally excluded controls with a recent (1 year 
before index date) craniotomy as some of these patients might 
have an unrecorded glioma diagnosis.
2.2.3 | Exposures
The exposures of interest in this study were AD and other 
immune-related disorders identified from CPRD electronic 
records: The autoimmune diseases included were inflamma-
tory bowel diseases (not specified, Crohn's disease, ulcerative 
colitis), Addison's disease, allergic enterocolitis, ankylosing 
spondylitis, antiphospholipid syndrome, autoimmune hemo-
lytic purpura, different forms of vasculitis (including aller-
gic purpura, Behcet's disease, Goodpasture syndrome, Churg 
Strauss disease, cryoglobulinaemic vasculitis, Takayasu ar-
teritis, polyarteritis nodosa, microscopic polyangiitis, giant 
cell arteritis, granulomatosis with polyangiitis, other vascu-
litis), autoimmune connective tissue diseases (lupus erythe-
matodes, scleroderma, Sjogren's syndrome), thyroid gland 
diseases (autoimmune parathyroiditis, chronic thyroiditis, 
Grave's disease, Hashimoto's disease, other thyroiditis), bil-
iary cirrhosis, chronic gastritis, Guillain Barré Bannwarth 
syndrome, coeliac disease, Jaccoud arthropathy, juvenile 
pemphigoid, myasthenia gravis, microscopic colitis, pem-
phigus, pernicious anemia, sarcoidosis, polymyalgia rheu-
matica, multiple sclerosis, psoriasis, rheumatic fever, Reiter's 
disease, thrombocytopenic purpura, type I diabetes, vitiligo, 
and rheumatoid arthritis (RA). Allergies in general were in-
cluded as a single variable in our analysis. We also investi-
gated associations between asthma, dermatitis, hay fever or 
other specific allergies and the risk of glioma separately.
We explored autoimmune diseases as a single variable, 
and separately for each specific disease entity. We also 
evaluated combined variables for inflammatory bowel 
diseases, thyroid gland diseases, vasculitis, and autoim-
mune connective tissue diseases due to limitations of small 
numbers.
We further defined a single variable for T-cell mediated 
diseases, which included Addison's disease, Crohn's disease, 
multiple sclerosis, RA, coeliac disease, Hashimoto's disease, 
psoriasis, type I diabetes, and sarcoidosis. We considered 
a patient exposed to one of the above diseases if she or he 
had at least one Read code for that disease recorded before 
the index date. Using the first listed Read code for each dis-
ease we calculated disease duration as the interval between 
the first record of each AD and the index date, and we cat-
egorized duration as short, intermediate or long (<5, 5-10, 
>10 years).
We also assessed exposure to immunosuppressive drugs 
that are frequently used to treat autoimmune diseases 
(systemic corticosteroids, inhaled corticosteroids, topical 
corticosteroids, mesalazine/5-ASA, azathioprine, mercapto-
purine, methotrexate, anti-TNF therapy, calcineurin inhibi-
tors, interleukin inhibitors, other immunosuppressants). We 
defined patients who received no prescription for the drugs 
in question as nonusers (reference). We categorized expo-
sure to immunosuppressive drugs based on the number of 
prescriptions of corticosteroids (0, 1-4, 5-9, ≥10) or other 
immunosuppressive drugs (0, 1-19, ≥20) before the index 
date.
2.3 | Statistical analyses
We conducted conditional logistic regression analyses to cal-
culate odds ratios (ORs) with 95% confidence intervals (CIs) 
of glioma for exposure to autoimmune diseases, by duration 
of the disease and for the use of immunosuppressive drugs. 
We used SAS version 9.4 (SAS Institute Inc) to conduct all 
analyses.
We evaluated the following covariates as potential con-
founders: smoking status (unknown, current, past, never), 
body mass index (unknown, <18.5, 18.5-24.9, 25.0-29.9, 
>30.0 kg/m2), use of NSAIDs (none, 1-9 prescriptions, ≥10 
prescriptions), statins (none, 1-9 prescriptions, ≥10 pre-
scriptions), and estrogens (none, 1-9 prescriptions, ≥10 pre-
scriptions). We only included variables that altered the risk 
of glioma by >10% in the final multivariate analyses. We 
performed subgroup analyses after stratification by glioma 
subtype, age, and sex.
We also tested linear trends of autoimmune disease 
duration and prescriptions of immunosuppressive drugs 
using a Wald test analogous to our previous descrip-
tions.29,30 When we investigated specific autoimmune 
diseases, we corrected for multiple testing controlling the 
False Discovery Rate at 5% according to the Benjamini-
Hochberg procedure.31
3 |  RESULTS
3.1 | Basic characteristics of cases and 
controls
We identified 3112 patients with incident glioma and 31 120 
matched controls who met the inclusion criteria. Mean (SD) 
length of history in the database before the index date was 
11.6 years (±5.6 years). On average, there were 9.1 practice 
visits per year in cases and 8.8 in controls. See Table 1 for 
information on basic characteristics of cases and controls are. 
We do not display cell sizes less than 5 in compliance with 
CPRD guidelines.
There were more male than female cases (55.0% male and 
45.0% female), and the mean age was 54.7 years. There were 
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646 cases (20.8%) with lower grade glioma (WHO grade I/II/
III), 1348 cases (43.3%) with glioblastoma (WHO grade IV), and 
1118 cases (35.9%) with glioma that was not further specified.
In univariate analyses, low BMI (underweight) was 
inversely associated (OR 0.36; 95% CI 0.21-0.62) to the 
risk of glioma compared to normal weight. Being a current 
smoker (OR 0.84, 95% CI 0.75-0.94) was also associated 
with a reduced risk of glioma compared to nonsmokers. 
Heart failure (OR 0.56, 95% CI 0.38-0.81) and past myo-
cardial infarction (OR 0.77, 95% CI 0.61-0.97) were in-
versely associated to the incidence of glioma, whereas a 
history of stroke, chronic obstructive pulmonary disease, 
hyperlipidemia, deep vein thrombosis, coronary heart dis-
ease, gout, and renal disease were not associated with an 
altered OR. Comedication with statins, NSAIDs, or estro-
gens (women only) also showed no significant relation to 
glioma risk. When we stratified by sex, congestive heart 
failure was associated with a reduced risk in male patients 
(OR 0.54, 95% CI 0.33-0.88). In female patients with gli-
oma, deep vein thrombosis was observed more often than 
in controls (OR 1.65, 95% CI 1.14-2.37). See Table 1 for 
details.
T A B L E  1  Demographic characteristics in cases and controls
 
Cases 
(n = 3112)
Controls 
(n = 31 120)
Crude  
OR (95% CI)Number (%) Number (%)
Sex
Male 1713 (55.0) 17 130 (55.0)  
Female 1399 (45.0) 13 990 (45.0)  
Age class
0-39 620 (19.9) 6194 (19.9)  
40-59 1011 (32.5) 10 093 (32.4)  
>=60 1481 (47.6) 14 833 (47.7)  
Mean age (y)
Mean (SD) 54.7 (19.4) 54.7 (19.4)  
Length of history before index date (y)
Mean (SD) 11.6 (5.6) 11.6 (5.6)  
BMI (kg/m2)
<18.5 14 (0.5) 376 (1.2) 0.36 (0.21-0.62)
18.5-24.9 907 (29.2) 8815 (28.3) 1.00 (reference)
25-29.9 927 (29.8) 8986 (28.9) 1.01 (0.91-1.11)
>=30 532 (17.1) 5217 (16.8) 1.00 (0.89-1.12)
Unknown 732 (23.5) 7726 (24.8) 0.88 (0.78-1.00)
Smoking status
Smoker 472 (15.2) 5172 (16.6) 0.84 (0.75-0.94)
Past smoker 738 (23.7) 7380 (23.7) 0.94 (0.85-1.03)
Non-smoker 1482 (47.6) 13 781 (44.3) 1.00 (reference)
Unknown 420 (13.5) 4787 (15.4) 0.71 (0.61-0.83)
Glioma subtype
Lower grade 
glioma WHO 
° I/II/III
646 (20.7) 6460 (20.8)  
Glioblastoma 
WHO ° IV
1348 (43.3) 13 480 (43.3)  
Not specified 1118 (35.9) 11 180 (35.9)  
Comorbidities
CHF 29 (0.9) 508 (1.6) 0.56 (0.38-0.81)
MI 82 (2.6) 1048 (3.4) 0.77 (0.61-0.97)
Stroke 105 (3.4) 1182 (3.8) 0.88 (0.72-1.08)
IHD 225 (7.2) 2392 (7.7) 0.93 (0.80-1.08)
Hyperlipidemia 305 (9.8) 3306 (10.6) 0.90 (0.79-1.03)
DVT 58 (1.9) 460 (1.5) 1.27 (0.96-1.67)
Gout 101 (3.3) 1133 (3.6) 0.88 (0.72-1.09)
Renal disease 85 (2.7) 778 (2.5) 1.10 (0.87-1.38)
COPD 73 (2.4) 881 (2.8) 0.82 (0.64-1.05)
Number of practice visits
0-9 2159 (69.4) 22 473 (72.2)  
20-29 204 (6.6) 1744 (5.6)  
(Continues)
 
Cases 
(n = 3112)
Controls 
(n = 31 120)
Crude  
OR (95% CI)Number (%) Number (%)
>=30 85 (2.7) 865 (2.8)  
Mean (SD) 9.09 (9.0) 8.76 (9.0)  
Comedication
Number of 
prescriptions
     
Statins
0 2557 (82.2) 25 735 (91.0) 1.00 (reference)
1-9 140 (4.5) 1251 (4.0) 1.14 (0.94-1.36)
>=10 415 (13.3) 4134 (13.3) 1.02 (0.90-1.16)
NSAIDs
0 1313 (42.2) 13 616 (43.8) 1.00 (reference)
1-9 1400 (45.0) 13 496 (43.4) 1.09 (1.00-1.18)
>=10 399 (12.8) 4008 (12.9) 1.046 (0.92-1.19)
Estrogens (women only)
0 1076 (76.9) 10 837 (77.5) 1.00 (reference)
1-9 233 (16.7) 2242 (16.0) 1.05 (0.90-1.24)
>=10 90 (6.4) 911 (6.4) 1.00 (0.79-1.27)
Note: Bold indicates significant value (P < .05).
Matching variables: calendar time (same index date), age (same year of birth), 
sex, general practice, and number of years of active history in the database prior 
to the index date.
Abbreviations: BMI, body mass index; CHF, congestive heart failure; CI, confi-
dence interval; COPD, chronic obstructive pulmonary disease; DVT, deep vein 
thrombosis; IHD, ischemic heart disease; MI, myocardial infarction; NSAIDs, 
nonsteroidal anti-inflammatory drugs; OR, odds ratio; SD, standard deviation.
T A B L E  1  (Continued)
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3.2 | Multivariate models
3.2.1 | Autoimmune diseases
We observed 282 (9.06%) cases with a recorded history of 
any autoimmune disease. There was no association between 
patients with any “autoimmune disease” and glioma risk (OR 
0.98, 95% CI 0.86-1.11). We also investigated combined 
variables for any inflammatory bowel disease (OR 1.28, 95% 
CI 0.95-1.71), any autoimmune connective tissue disease 
(OR 1.10, 95% CI 0.50-2.41), any thyroid gland disease (OR 
1.15, 95% CI 0.59-2.21), and any vasculitis (OR 1.07, 95% 
CI 0.79-1.47), none of which were associated with risk of 
glioma.
When we analyzed the data for the various autoimmune 
diseases separately (Table 2), none of them were related to an 
altered risk of glioma. There were also no statistically signif-
icant associations between Crohn's disease (OR 0.96, 95% CI 
0.48-1.90), ulcerative colitis (OR 1.27, 95% CI 0.85-1.88), or 
inflammatory bowel disease not further specified (OR 1.27, 
95% CI 0.81-1.98), and the risk of glioma. A statistically 
nonsignificant reduced risk of glioma of >20% was observed 
for type I diabetes, rheumatic fever, sarcoidosis, and coeliac 
disease. We observed a statistically nonsignificant increased 
risk for pernicious anemia, Hashimoto, Sjogren's syndrome, 
and vitiligo (Table 2).
Upon stratification by sex, we observed no divergent re-
sults between males and females (data not shown).
3.2.2 | Allergies
Of all patients with glioma, 1219 (39.17%) had a history of 
some allergic condition (Table 2). We observed no altered 
glioma risk among patients with “any allergy” (OR 0.97, 95% 
CI 0.89-1.05) or with any of the specific allergic conditions.
3.2.3 | Glioma subtypes
We also analyzed the different glioma subtypes separately 
to see if the results differed according to type (Table 3). For 
methodologic reasons (Read Codes do not always differenti-
ate well between WHO grade I, II, and III glioma), we distin-
guished between grades I/II/III (lower grade) and grade IV 
glioma.
In WHO grades I/II/III gliomas, IBD and specifically 
ulcerative colitis, were the only exposures that were asso-
ciated with statistically significantly increased ORs for gli-
oma (OR 2.15, 95% CI 1.17-3.96 for IBD, and OR 2.56, 95% 
CI 1.22-5.37 for ulcerative colitis). When we took multiple 
testing into account, the results were no longer statistically 
significant.
T A B L E  2  Risk of glioma in patients with immune-related 
disorders and autoimmune diseases
 
Cases 
(n = 3112)
Controls 
(n = 31 120)
Adjusted OR 
(95% CI)Number (%) Number (%)
Immune-related disorders
Diabetes 204 (5.6) 2295 (7.4) 0.86 (0.73-1.00)
Allergies
Any allergya 1219 (39.2) 12 291 (39.5) 0.97 (0.89-1.05)
Asthma 342 (11.0) 3621 (11.6) 0.91 (0.81-1.03)
Dermatitis 828 (26.6) 8093 (26.0) 1.02 (0.94-1.11)
Hay fever 299 (9.6) 2843 (9.1) 1.04 (0.91-1.18)
Other allergies 157 (5.0) 1660 (5.3) 0.93 (0.78-1.10)
Autoimmune diseases
Any autoimmune 
disease
282 (9.1) 2871 (9.2) 0.98 (0.86-1.11)
Other combined variables
T-cell mediated 190 (6.1) 2113 (6.8) 0.89 (0.76-1.04)
Connective tissue 
disease
7 (0.2) 63 (0.2) 1.10 (0.50-2.41)
IBD 52 (1.7) 406 (1.3) 1.28 (0.95-1.71)
Thyroid gland 
diseases
10 (0.3) 87 (0.3) 1.15 (0.59-2.21)
Vasculitis—any 
(including PMR)
46 (1.5) 423 (1.4) 1.07 (0.79-1.47)
Vasculitis (without 
PMR)
11 (0.4) 135 (0.4) 0.81 (0.44-1.49)
Specific autoimmune diseases
Ankylosing 
spondylitis
8 (0.3) 71 (0.2) 1.12 (0.54-2.33)
Coeliac disease 6 (0.2) 82 (0.3) 0.73 (0.32-1.67)
Crohn's disease 9 (0.3) 93 (0.3) 0.96 (0.48-1.90)
Diabetes type I 5 (0.2) 82 (0.3) 0.59 (0.24-1.46)
Hashimoto 5 (0.2) 22 (0.1) 2.30 (0.87-6.09)
IBD-not specified 22 (0.7) 175 (0.6) 1.27 (0.81-1.98)
Multiple sclerosis 9 (0.3) 85 (0.3) 1.06 (0.53-2.11)
Pernicious anemia 15 (0.5) 104 (0.3) 1.46 (0.85-2.52)
PMR 35 (1.1) 288 (0.9) 1.20 (0.84-1.72)
Psoriasis 104 (3.3) 1136 (3.7) 0.92 (0.75-1.13)
Rheumatic fever 5 (0.2) 75 (0.2) 0.66 (0.27-1.63)
RA 53 (1.7) 596 (1.9) 0.89 (0.67-1.18)
Sarcoidosis 6 (0.2) 81 (0.3) 0.72 (0.31-1.65)
Sjogren's syndrome 5 (0.2) 31 (0.1) 1.54 (0.60-3.99)
Ulcerative colitis 28 (0.9) 218 (0.7) 1.27 (0.85-1.88)
Vitiligo 11 (0.4) 82 (0.3) 1.31 (0.70-2.46)
Note: Adjusted for: smoking and BMI.
Matching variables: calendar time (same index date), age (same year of birth), 
sex, general practice, and number of years of active history in the database prior 
to the index date.
Abbreviations: CI, confidence interval; IBD, inflammatory bowel disease; OR, 
odds ratio; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis.
aAny allergy: combined variable for asthma, dermatitis, hay fever and other allergies. 
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With regard to the risk of glioblastoma, we did not observe 
relations to autoimmune diseases in general (OR 0.98, 95% CI 
0.81-1.18), nor did we observe associations between any of the 
other specific autoimmune diseases and risk of glioblastoma, 
except for diabetes (combined variable for type I and type II) 
(OR 0.79, 95% CI 0.64-0.98). The result was not statistically 
significant after correction for multiple comparisons.
3.3 | Restriction to young patients and 
patients with longer survival
The two significant associations observed in this study were 
found in WHO grade I/II/III glioma cases with a history of 
IBD and ulcerative colitis, both of which tend to occur in 
younger patients. Therefore, we conducted further analysis 
restricted to cases and their corresponding controls who were 
below 40 years of age. Among those, patients with a record 
of IBD had an increased risk of glioma (OR 2.59, 95% CI 
1.31-5.12, compared to 1.28 among all glioma patients). See 
Table 3 for details.
When we restricted the analysis of all gliomas to pa-
tients with an overall survival of ≥20 months, again inflam-
matory bowel disease was associated with an elevated risk 
of glioma after correction for multiple testing (OR 2.10, 
95% CI 1.30-3.38). There was also an increased risk asso-
ciated with coeliac disease (OR 3.72, 95% CI 1.32-10.46). 
Furthermore, in this subgroup, asthma was inversely 
T A B L E  3  Risk of glioma subtypes in patients with immune-
related disorders and autoimmune diseases
Glioma WHO ° I/
II/III
Cases 
(n = 646)
Controls 
(n = 6460)
Adjusted OR 
(95% CI)Number (%) Number (%)
Immune-related disorders
Diabetes 20 (3.1) 221 (3.4) 0.88 (0.54-1.42)
Allergies
Any allergy 254 (39.3) 2664 (41.2) 0.91 (0.76-1.08)
Asthma 70 (10.8) 848 (13.1) 0.78 (0.59-1.01)
Dermatitis 176 (27.2) 1729 (26.8) 1.02 (0.84-1.24)
Hay fever 72 (11.2) 658 (10.2) 1.11 (0.85-1.44)
Other allergies 25 (3.9) 322 (5.0) 0.77 (0.50-1.17)
Autoimmune diseases
Any autoimmune 
disease
51 (7.9) 440 (6.8) 1.18 (0.87-1.60)
Other combined variables
T-cell mediated 36 (5.6) 332 (5.1) 1.09 (0.76-1.56)
IBD 13 (2.0) 61 (0.9) 2.15 (1.17-3.96)
Vasculitis—any 
(including PMR)
5 (0.8) 41 (0.6) 1.22 (0.48-3.11)
Specific autoimmune diseases
Psoriasis 21 (3.3) 208 (3.2) 1.01 (0.63-1.59)
RA 9 (1.4) 72 (1.1) 1.26 (0.62-2.54)
Ulcerative colitis 9 (1.4) 35 (0.5) 2.56 (1.22-5.37)
Glioblastoma 
WHO ° IV
Cases 
(n = 1348)
Controls 
(n = 13 480)
Crude OR (95% 
CI)Number (%) Number (%)
Immune-related disorders
Diabetes 105 (7.8) 1276 (9.5) 0.79 (0.64-0.98)
Allergies
Any allergy 538 (39.9) 5281 (39.2) 1.02 (0.91-1.15)
Asthma 146 (10.8) 1455 (10.8) 1.00 (0.83-1.20)
Dermatitis 363 (26.9) 3533 (26.2) 1.03 (0.90-1.18)
Hay fever 140 (10.4) 1196 (8.9) 1.18 (0.98-1.43)
Other allergies 73 (5.4) 775 (5.8) 0.92 (0.72-1.19)
Autoimmune diseases
Any autoimmune 
disease
136 (10.1) 1394 (10.3) 0.98 (0.81-1.18)
Other combined variables
T-cell mediated 100 (7.4) 1042 (7.7) 0.96 (0.77-1.19)
IBD 25 (1.9) 199 (1.5) 1.28 (0.84-1.94)
Thyroid gland 
diseases
7 (0.5) 45 (0.3) 1.54 (0.69-3.42)
Vasculitis—
any (including 
PMR)
16 (1.2) 206 (1.5) 0.76 (0.46-1.27)
Glioblastoma 
WHO ° IV
Cases 
(n = 1348)
Controls 
(n = 13 480)
Crude OR (95% 
CI)Number (%) Number (%)
Specific autoimmune diseases
Ankylosing 
spondylitis
5 (0.4) 33 (0.2) 1.54 (0.60-3.95)
IBD-not specified 12 (0.9) 84 (0.6) 1.45 (0.79-2.66)
Multiple sclerosis 5 (0.4) 49 (0.4) 1.02 (0.41-2.56)
Pernicious 
anemia
5 (0.4) 61 (0.5) 0.82 (0.33-2.06)
PMR 13 (1.0) 142 (1.1) 0.90 (0.51-1.60)
Psoriasis 54 (4.0) 515 (3.8) 1.06 (0.80-1.42)
RA 28 (2.1) 327 (2.4) 0.85 (0.58-1.26)
Ulcerative colitis 11 (0.8) 100 (0.7) 1.10 (0.59-2.06)
Vitiligo 5 (0.4) 37 (0.3) 1.30 (0.51-3.32)
Note: Bold indicates significant value (P < .05).
Adjusted for: smoking and BMI.
Matching variables: calendar time (same index date), age (same year of birth), 
sex, general practice, and number of years of active history in the database prior 
to the index date.
Abbreviations: CI, confidence interval; IBD, inflammatory bowel disease; OR, 
odds ratio; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis.
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related to the risk of glioma (OR 0.73, 95% CI 0.58-0.91). 
After correction for multiple testing, both effects remained 
statistically significant.
3.4 | Disease duration
To assess the influence of AD duration on the risk of glioma, 
we looked at different times from autoimmune disease onset 
to index date (Table 4). We observed no effect of disease 
duration (<5, 5-10, ≥10  years) on glioma for autoimmune 
diseases, allergies, or specific allergic conditions. However, 
recent onset (<5 years) of inflammatory bowel disease (OR 
1.69, 95% CI 1.04-2.76) or ulcerative colitis (OR 2.24, 95% 
CI 1.08-4.63) was associated with an increased risk of gli-
oma. We observed a trend for a reduced risk of glioma in 
patients with longer duration of diabetes.
3.5 | Corticosteroids and 
immunosuppressive drugs
There was no altered glioma risk associated with use of cor-
ticosteroids, systemic corticosteroids, or use of any immu-
nosuppressive drug. The risk did not change for any of these 
exposures when we evaluated the effect according to dura-
tion of use (Table 5).
4 |  DISCUSSION
In this population-based case-control study, autoimmune 
diseases, allergies, and use of immunosuppressive agents 
were not related to an altered risk of glioma. This finding 
is consistent with a couple of published studies that came 
to the same conclusion.16,25 However, only few studies spe-
cifically addressed glioma risk in relation to subgroups of 
autoimmune diseases. A cohort study that included around 
4.5 million US veterans found no significant association 
between autoimmune diseases in general or any of the 
other specific autoimmune conditions that were investi-
gated, including asthma, multiple sclerosis, ulcerative co-
litis, Crohn's disease, and the risk of glioma.16 A Swedish 
retrospective cohort study based on the Swedish Hospital 
Discharge Register also found no association between any 
of the 33 autoimmune diseases examined, including RA, 
multiple sclerosis, ulcerative colitis, Crohn's diseases, and 
risk of glioma.25
However, some publications that have investigated pos-
sible environmental influences on glioma have found a 
lower risk in patients with a history of AD.15,22 One of them 
was a case-control study with 489 patients based on data 
obtained in three hospitals in the United States. The authors 
described a lower glioma risk in patients with autoimmune 
diseases in general, however, no association was found with 
specific autoimmune disease including RA, multiple scle-
rosis, lupus erythematosus, and pernicious aaemia.15
Interestingly, in our study there was a suggestion of an el-
evated risk of glioma among patients with a history of IBD, 
when we just examined patients with lower grade glioma (LGG) 
(WHO I, II, and III), patients with better overall survival, or 
patients below the age of 40 years. This contrasts with the re-
sults from other studies, which found no significant relation be-
tween glioma risk and the history of the inflammatory bowel 
disease.16,25 However, those studies did not conduct analyses by 
specific subgroups of patients. Separate analyses for LGG and 
high-grade gliomas (HGG) were performed in only one retro-
spective cohort study from Sweden.25 In contrast to our study, 
the authors of that study applied another categorization with re-
gard to glioma grades. They defined LGG as WHO grade I and 
II, whereas HGG was defined as WHO grade III and IV (with 
only few cases in the low grade glioma subgroup).25 Of note, 
categorizing WHO glioma grades as I/II/III vs grade IV may 
be more appropriate on a genetic level than comparing WHO 
grade I/II vs grade III/IV, which may explain the null results 
in the Swedish study. Most WHO grade II and III gliomas are 
almost exclusively isocitrate dehydrogenase (IDH)-mutated, 
whereas glioblastoma is not and IDH mutation and occurs more 
often in younger patients.32
Several mechanisms could explain an association be-
tween IBD and the microbiota on the brain. IBD such as 
Crohn's disease and ulcerative colitis are characterized by 
impaired intestinal barrier function.33 Such impaired bar-
rier function may enable certain bacterial components to 
reach the intestinal epithelium, known as “bacterial trans-
location”, a mechanism that is hypothesized to play a role 
in carcinogenesis.34 Patients with ulcerative colitis show 
increased levels of serum transforming growth factor-β1 
(TGF- β1).35,36 Another study found that TGF-β produc-
tion was increased in Clostridium-colonized mice, and that 
formation of Tregs was induced,37 indicating an involve-
ment of the intestinal microbiota in the modulation of the 
peripheral immune system. In glioma patients, TGF-β has 
been shown to be upregulated and to take part importantly 
in glioma initiation and proliferation.38 Other mechanisms 
that could explain how alterations of the microbiota can 
affect the brain involve activation of the vagus nerve,39 
neuroimmune pathways,40 microbial metabolites,41 and 
microbial-derived neurotransmitters.42 For example, mi-
crobiota-derived short-chain fatty acids control microglia 
maturation and function.41
In solid tumors other than malignant glioma, increasing ev-
idence suggests meaningful associations between alterations 
of the intestinal microbiota and colorectal carcinoma,43-46 he-
patocellular carcinoma,47,48 and breast cancer,49 among oth-
ers. Furthermore, it is well documented that the microbiota is 
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involved in CNS-pathologies such as Parkinson's disease50 or 
multiple sclerosis.51 A recent mouse model showed that in-
creased intestinal Th17 cells and aggravation of experimentally 
T A B L E  4  Risk of glioma in patients with immune-related 
disorders and autoimmune diseases by time since diagnosis
 
Cases 
(n = 3112)
Controls 
(n = 31 120)
Adjusted OR 
(95% CI)Number (%) Number (%)
Immune-related disorders
Diabetes
0 2908 (93.4) 28828 (92.6) 1
<5 y 100 (3.2) 942 (3.0) 1.03 (0.83-1.28)
5-10 y 54 (1.7) 678 (2.2) 0.76 (0.58-1.02)
>10 y 50 (1.6) 672 (2.2) 0.71 (0.53-0.96)
Allergies
Any allergy
0 1904 (61.2) 18 910 (60.8) 1
<5 y 321 (10.3) 3078 (9.9) 1.02 (0.90-1.16)
5-10 y 321 (10.3) 3175 (10.2) 0.98 (0.86-1.12)
>10 y 566 (18.2) 5957 (19.1) 0.91 (0.82-1.08)
Asthma
0 2776 (89.2) 27 544 (88.5) 1
<5 y 63 (2.0) 708 (2.3) 0.86 (0.66-1.12)
5-10 y 77 (2.5) 842 (2.7) 0.88 (0.69-1.12)
>10 y 196 (6.3) 2026 (6.5) 0.94 (0.80-1.10)
Dermatitis
0 2285 (73.4) 23 047 (74.1) 1
<5 y 272 (8.7) 2491 (8.0) 1.09 (0.95-1.25)
5-10 y 235 (7.6) 2275 (7.3) 1.03 (0.89-1.19)
>10 y 320 (10.3) 3307 (10.6) 0.96 (0.84-1.10)
Hay fever
0 2816 (90.5) 28 300 (90.9) 1
<5 y 82 (2.6) 747 (2.4) 1.08 (0.86-1.36)
5-10 y 85 (2.7) 715 (2.3) 1.18 (0.94-1.49)
>10 y 129 (4.2) 1358 (4.4) 0.93 (0.77-1.13)
Other allergies
0 2959 (95.1) 29 497 (94.8) 1
<5 y 48 (1.5) 516 (1.7) 0.91 (0.68-1.23)
5-10 y 42 (1.4) 460 (1.5) 0.89 (0.64-1.23)
>10 y 63 (2.0) 647 (2.1) 0.95 (0.73-1.25)
Autoimmune diseases
Any autoimmune disease
0 2831 (91.0) 28 263 (90.8) 1
<5 y 71 (2.3) 802 (2.6) 0.88 (0.69-1.13)
5-10 y 76 (2.4) 648 (2.1) 1.17 (0.92-1.49)
>10 y 134 (4.3) 1407 (4.5) 0.95 (0.79-1.14)
Other combined variables
IBD
0 3060 (98.3) 30 716 (98.7) 1
(Continues)
 
Cases 
(n = 3112)
Controls 
(n = 31 120)
Adjusted OR 
(95% CI)Number (%) Number (%)
<5 y 19 (0.6) 113 (0.4) 1.69 (1.04-2.76)
5-10 y 10 (0.3) 83 (0.3) 1.21 (0.63-2.33)
>10 y 23 (0.7) 208 (0.7) 1.10 (0.71-1.69)
Vasculitis—any (including PMR)
0 3066 (98.5) 30 698 (98.6) 1
<5 y 18 (0.6) 189 (0.6) 0.94 (0.57-1.53)
5-10 y 14 (0.5) 130 (0.4) 1.07 (0.61-1.86)
>10 y 14 (0.5) 103 (0.3) 1.34 (0.77-2.36)
Specific autoimmune diseases
IBD-not specified
0 3090 (99.3) 30 946 (99.4) 1
<5 y 9 (0.3) 65 (0.2) 1.40 (0.69-2.82)
5-10 y 6 (0.2) 42 (0.1) 1.43 (0.61-3.36)
>10 y 7 (0.2) 67 (0.2) 1.06 (0.48-2.30)
PMR
0 3077 (98.9) 30 832 (99.1) 1
<5 y 16 (0.5) 144 (0.5) 1.10 (0.65-1.85)
5-10 y 11 (0.4) 85 (0.3) 1.28 (0.68-2.41)
>10 y 8 (0.3) 59 (0.2) 1.35 (0.64-2.84)
Psoriasis
0 3009 (96.7) 29 991 (96.4) 1
<5 y 25 (0.8) 299 (1.0) 0.84 (0.56-1.27)
5-10 y 25 (0.8) 256 (0.8) 0.98 (0.64-1.47)
>10 y 53 (1.7) 574 (1.8) 0.92 (0.69-1.23)
RA
0 3059 (98.3) 30 527 (98.1) 1
<5 y 13 (0.4) 163 (0.5) 0.79 (0.45-1.39)
5-10 y 16 (0.5) 145 (0.5) 1.09 (0.65-1.83)
>10 y 24 (0.8) 285 (0.9) 0.85 (0.56-1.29)
Ulcerative colitis
0 3084 (99.1) 30 902 (99.3) 1
<5 y 9 (0.3) 41 (0.1) 2.24 (1.08-4.63)
5-10 y 5 (0.2) 52 (0.2) 0.95 (0.38-2.39)
>10 y 14 (0.5) 125 (0.4) 1.09 (0.63-1.90)
Note: Bold indicates significant value (P < .05).
Adjusted for: smoking and BMI.
Matching variables: calendar time (same index date), age (same year of birth), 
sex, general practice, and number of years of active history in the database prior 
to the index date.
Abbreviations: CI, confidence interval; IBD, inflammatory bowel disease; OR, 
odds ratio; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis.
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induced autoimmune encephalomyelitis by high salt diet can be 
prevented by administration of certain lactobacillus species.52 
It is therefore conceivable that alterations of the intestinal mi-
crobiota have a part in the pathogenesis of lower-grade glioma.
Tregs play an important role in the pathophysiology of 
glioma by contributing to an immunosuppressive milieu.53 To 
account for alterations in T-cell function and to include more 
cases of autoimmune diseases of a common pathophysiology 
in our analysis, we investigated the risk of glioma in patients 
with a history of AD, which are considered T-cell mediated. 
However, no particular association was observed. A possible 
explanation is that even AD such as multiple sclerosis, which 
are considered T-cell mediated, involve numerous other ele-
ments of the immune system.54 A joint examination of these 
diseases on the premise that they share a common pathophys-
iological pathway may therefore be too simplistic.
We observed no overall association between a diagnosis of 
allergy in general or different allergies and glioma risk in our 
study. However, we found an inverse relation between asthma 
and incidence of glioma in patients below 40 years of age 
after correction for multiple testing. Several other case-con-
trol studies,15,17,55-59 cohort studies 16,23,24, and meta-analyses 
18,20,21 have already investigated the relation between allergic 
T A B L E  5  Risk of glioma in relation to corticosteroids and other 
immunosuppressive drugs
 
Cases 
(n = 3112)
Controls 
(n = 31 120)
Adjusted OR 
(95% CI)Number (%) Number (%)
Inhalative corticosteroids
No prescription 2726 (87.6) 27 073 (87.0) 1
Any prescription 386 (12.4) 4047 (13.0) 0.93 (0.83-1.04)
1-4 
prescriptions
154 (5.0) 1429 (4.6) 1.05 (0.88-1.25)
5-9 
prescriptions
40 (1.3) 549 (1.8) 0.70 (0.51-0.97)
>=10 
prescriptions
192 (6.2) 2069 (6.7) 0.91 (0.78-1.06)
Systemic corticosteroids
No prescription 2312 (74.3) 23 261 (74.8) 1
Any prescription 800 (25.7) 7859 (25.3) 1.02 (0.93-1.11)
1-4 
prescriptions
617 (19.8) 6004 (19.3) 1.03 (0.93-1.13)
5-9 
prescriptions
89 (2.9) 883 (2.8) 1.01 (0.81-1.27)
>=10 
prescriptions
94 (3.0) 972 (3.1) 0.97 (0.78-1.21)
Topic corticosteroids
No prescription 1235 (39.7) 13 058 (42.0) 1
Any prescription 1877 (60.3) 18 062 (58.0) 1.09 (1.01-1.18)
1-4 
prescriptions
1198 (38.5) 11 351 (36.5) 1.11 (1.01-1.21)
5-9 
prescriptions
323 (10.4) 3118 (10.0) 1.08 (0.94-1.23)
>=10 
prescriptions
356 (11.4) 3593 (11.6) 1.04 (0.91-1.18)
Other immunosuppressive drugs
Any immunosuppressive drug
No prescription 3042 (97.8) 30 429 (97.8) 1
Any prescription 70 (2.3) 691 (2.2) 1.01 (0.79-1.30)
1-19 
prescriptions
40 (1.3) 435 (1.4) 0.92 (0.66-1.27)
>=20 
prescriptions
30 (1.0) 256 (0.8) 1.16 (0.80-1.71)
Mesalazine/5-ASA
No prescription 3063 (98.4) 30 673 (98.6) 1
Any prescription 49 (1.6) 447 (1.4) 1.08 (0.80-1.46)
1-19 
prescriptions
26 (0.8) 256 (0.8) 1.01 (0.67-1.51)
>=20 
prescriptions
23 (0.7) 191 (0.6) 1.18 (0.77-1.83)
Azathioprine
No prescription 3101 (99.7) 30 968 (99.5) 1
(Continues)
 
Cases 
(n = 3112)
Controls 
(n = 31 120)
Adjusted OR 
(95% CI)Number (%) Number (%)
Any prescription 11 (0.4) 152 (0.5) 0.72 (0.39-1.33)
1-19 
prescriptions
5 (0.2) 88 (0.3) 0.56 (0.23-1.38)
>=20 
prescriptions
6 (0.2) 64 (0.2) 0.95 (0.41-2.20)
Methotrexate
No prescription 3095 (99.5) 30 914 (99.3) 1
Any prescription 17 (0.6) 206 (0.7) 0.82 (0.50-1.36)
1-19 
prescriptions
5 (0.2) 86 (0.3) 0.58 (0.24-1.44)
>=20 
prescriptions
12 (0.4) 120 (0.4) 1.00 (0.55-1.81)
Other immunosuppressive drugs
No prescription 3085 (99.1) 30 785 (98.9) 1
Any prescription 27 (0.9) 335 (1.1) 0.80 (0.54-1.19)
1-19 
prescriptions
9 (0.3) 153 (0.5) 0.58 (0.30-1.14)
>=20 
prescriptions
18 (0.6) 182 (0.6) 0.99 (0.61-1.61)
Note: Bold indicates significant value (P < .05).
Adjusted for: smoking and BMI.
Matching variables: calendar time (same index date), age (same year of birth), 
sex, general practice, and number of years of active history in the database prior 
to the index date.
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conditions and the risk of glioma. Most case-control studies 
observed an inverse association between some allergic dis-
ease and the risk of glioma.15,17,56-59
For example, in a study including 489 patients with gli-
oma, the authors observed an inverse association between the 
history of any allergy, asthma, and allergy to chemicals, and 
the risk of glioma.15 Allergies and infections were related to 
a reduced risk of glioma in a case-control study based on data 
from eight hospitals in six countries including 1178 cases.17
On the other hand, there is also a German case-control 
study with 366 glioma cases which did not find statistically 
significant associations.55
Most of these studies differ from ours, because they were 
interview- or questionnaire-based and might therefore have 
been prone to reporting bias. Additionally, information was 
often provided by proxy-respondents and not by the cases 
themselves. It is conceivable, that underreporting of allergy/
atopy occurs in cases more frequently than in controls due to 
cognitive impairment of patients with brain tumors. Proxy 
respondents might not know all allergic conditions. In our 
study medical records exist only if diagnoses were reported 
to the physician. Our data indicate that, before the index date, 
controls might be in poor health compared to cases as they 
are more likely to have a history of myocardial infarction and 
congestive heart failure. Underreporting of less serious issues 
such as allergic conditions seems plausible in sick persons, 
which could possibly mute inverse associations observed in 
previous case-control-studies. However, in our study, preva-
lence of any allergy was 39.2% in cases and 39.5% in con-
trols which is similar to the prevalence of allergic conditions 
in controls in a couple of other case-control studies.15,58,59
In general, cohort studies are more valid in providing 
information on causal relationships. The first cohort study 
that investigated the association between allergies and the 
risk of glioma included persons from the Swedish Twin 
Registry birth cohort who were grouped into cohorts I-III 
according to the year of birth.24 In cohorts I and III they ob-
served a reduced hazard ratio after the history of allergy.24 
However, results were not significant and there were only 
six and three exposed cases in cohorts I and III respectively. 
Cohort II showed no association with a slightly increased 
hazard ratio.24
In a cohort of male US veterans with 192 out of 4383 gli-
oma cases (4.38%) exposed to allergy/atopy, there was a non-
significant correlation between allergy with latency >2 years 
and risk of brain tumors.16 A statistically significant trend of 
decreasing risk of brain cancer was observed with longer la-
tency of allergy.16 Another cohort study based on the Swedish 
population which investigated the risk of various cancers in-
cluding brain cancer observed no significant association with 
regard to the risk of brain tumors.23 Another cohort study in 
Taiwan found an increased risk of brain tumors after history 
of allergic rhinitis or asthma.60
Three meta-analyses which included most of the case-con-
trol studies cited above also found an inverse relation between 
allergy and glioma.18,20,21
Three other studies based on prospective cohorts found 
inverse associations of increased61,62 or borderline63 pre-di-
agnostic serum IgE levels and the risk of glioma and thus 
provide further evidence for the involvement of the immune 
system.
Gliomas are characterized by an immunosuppressive 
microenvironment and systemic immunosuppression.53 
Therefore, it is conceivable that immunosuppression itself 
might be a tumor promoting factor. However, in our analy-
sis no relation between immunosuppressive therapies and the 
incidence of gliomas became apparent. To date, few studies 
have systematically investigated the risk of glioma with re-
gard to prescription of immunosuppressants. Our findings 
are in accordance with a meta-analysis, which suggested 
no increased rates of brain cancer in patients with immuno-
suppressive therapy after organ transplantation, whereas in-
cidence of not specified brain cancer was higher in patients 
with acquired immune deficiency syndrome.64 There is also 
evidence that risk of other tumor entities is associated with 
duration of immunosuppressive therapy.65 In contrast, in our 
study, duration of treatment with immunosuppressive drugs 
was not associated with the incidence of glioma. Further 
stratification was limited because only few cases could be 
identified that were exposed to individual immunosuppres-
sive drugs.
We observed a slightly reduced risk of any glioma in pa-
tients with a history of diabetes. The inverse association was 
stronger among patients with type I diabetes (OR 0.59, 95% 
CI 0.24-1.46) than among patients with not specified diabetes 
(OR 0.86, 95% CI 0.73-1.00), but the results for type I diabe-
tes were only based on five cases.
We also observed an inverse association between diabetes 
in general (type I and type II) and the risk of glioblastoma. 
Furthermore, longer duration of diabetes (type I and type II) 
was inversely related to the risk of glioma. Interestingly, a 
reduced risk of glioma was described previously in patients 
with diabetes both in case-control studies 15,30,66,67 and pro-
spective cohort studies,16,68-70 indicating that a high blood 
glucose level might be inversely related to glioma risk. 
Possible underlying mechanism have already been discussed 
in detail in these previous studies,30,69 however, those studies 
often had no information on the type of diabetes.15,16,30,66-68,70
Several limitations of our study should be mentioned. 
We had no information on molecular alterations in pa-
tients with glioma, which are more accurate in describing 
the biological behavior of glioma subtypes than histology 
alone.32,71 As these alterations have only been determined 
in recent years, they are not available in epidemiologic stud-
ies covering longer observation periods. Because the data 
are based on primary health care data and because general 
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practitioners record the diagnoses, misclassification is pos-
sible. However, the accuracy of the CPRD GOLD has been 
repeatedly demonstrated.27 Adjustment for socioeconomic 
status and lifestyle factors was not possible because this 
kind of information is not regularly recorded in our data-
base. Nonetheless, cases and controls were matched on gen-
eral practitioner, which serves as a proxy for socioeconomic 
status since people from the same area are likely to be of 
comparable social class. Furthermore, other studies that as-
sessed socioeconomic status did not find significant associ-
ations with glioma risk.72,73 However, we have to point out 
that controls were more likely than cases to be smokers and 
have a low BMI. Smoking is known to be prevalent more 
often in lower socioeconomic classes.74 This could also ex-
plain why heart failure and myocardial infarction occurred 
more frequently in controls. It is therefore conceivable, that 
these patients exhibit higher levels of immune dysfunction 
which could affect prevalence of other immune-related dis-
orders in some way. We implemented smoking status and 
BMI as potential confounders into our multivariate model. 
Nonetheless, we cannot fully exclude confounding by so-
cioeconomic status in our study. Finally, our results for 
lower grade glioma and younger patients with glioma were 
based on few cases only and must therefore be interpreted 
with caution.
Our study has several strengths. The CPRD contains med-
ical records of more than 11 million people and has been 
found to be representative of the British population.26 In this 
large case-control study, we included 3112 patients with gli-
oma, more than most other studies investigating the effect of 
immune-associated disorders on the incidence of gliomas. 
Unlike many other case-control studies, the information an-
alyzed in our study was not self-reported, but collected pro-
spectively by health care professionals in the absence of any 
study hypothesis, rendering the data more accurate and re-
ducing potential recall-bias. Nonetheless, it is possible that 
not all diagnoses such as for example, hay fever are properly 
reported to physicians, especially if patients have more seri-
ous diseases to discuss.
In conclusion, we found no material associations between 
autoimmune diseases, allergies, or immunosuppressive ther-
apies and the risk of glioma. However, the risk of glioma 
was reduced in patients with longer duration of diabetes. 
Subgroup analyses in patients less than 40 years of age indi-
cated a positive association between inflammatory bowel dis-
eases and the risk of glioma. There was also a suggestion of 
an inverse relation between asthma and incidence of glioma 
especially in younger patients.
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